HCA Healthcare, Inc. $HCA Shares Sold by Lee Danner & Bass Inc.

Lee Danner & Bass Inc. lessened its stake in HCA Healthcare, Inc. (NYSE:HCA) by 0.8% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 393,654 shares of the company’s stock after selling 3,242 shares during the quarter. HCA Healthcare comprises approximately 12.2% of Lee Danner & Bass Inc.’s holdings, making the stock its biggest holding. Lee Danner & Bass Inc.’s holdings in HCA Healthcare were worth $167,775,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in HCA. Ameriflex Group Inc. purchased a new position in shares of HCA Healthcare in the 2nd quarter worth about $27,000. Chung Wu Investment Group LLC acquired a new stake in HCA Healthcare during the 2nd quarter worth approximately $27,000. Clearstead Trust LLC lifted its position in HCA Healthcare by 311.8% during the second quarter. Clearstead Trust LLC now owns 70 shares of the company’s stock valued at $27,000 after buying an additional 53 shares in the last quarter. Harbor Capital Advisors Inc. increased its position in shares of HCA Healthcare by 82.9% in the third quarter. Harbor Capital Advisors Inc. now owns 75 shares of the company’s stock worth $32,000 after acquiring an additional 34 shares in the last quarter. Finally, Twin Peaks Wealth Advisors LLC purchased a new stake in HCA Healthcare during the 2nd quarter worth $40,000. Hedge funds and other institutional investors own 62.73% of the company’s stock.

HCA Healthcare Price Performance

HCA opened at $469.08 on Tuesday. The stock has a market capitalization of $107.04 billion, a PE ratio of 18.13, a P/E/G ratio of 1.29 and a beta of 1.36. HCA Healthcare, Inc. has a 12-month low of $295.00 and a 12-month high of $520.00. The firm’s fifty day moving average price is $480.68 and its 200 day moving average price is $431.78.

HCA Healthcare (NYSE:HCA) last issued its earnings results on Friday, October 24th. The company reported $6.96 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.64 by $1.32. The business had revenue of $19.16 billion for the quarter, compared to analyst estimates of $18.55 billion. HCA Healthcare had a net margin of 8.53% and a negative return on equity of 792.25%. The company’s revenue for the quarter was up 9.6% on a year-over-year basis. During the same quarter in the prior year, the business posted $4.90 EPS. HCA Healthcare has set its FY 2025 guidance at 27.000-28.000 EPS. On average, equities research analysts forecast that HCA Healthcare, Inc. will post 24.98 earnings per share for the current fiscal year.

HCA Healthcare Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, December 29th. Investors of record on Monday, December 15th were given a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend was Monday, December 15th. HCA Healthcare’s dividend payout ratio is currently 11.13%.

Insider Buying and Selling

In other HCA Healthcare news, EVP Michael R. Mcalevey sold 3,892 shares of HCA Healthcare stock in a transaction on Wednesday, November 5th. The shares were sold at an average price of $473.79, for a total value of $1,843,990.68. Following the completion of the transaction, the executive vice president owned 3,487 shares of the company’s stock, valued at $1,652,105.73. The trade was a 52.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. 1.30% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of research analysts have commented on HCA shares. Royal Bank Of Canada boosted their price objective on HCA Healthcare from $482.00 to $525.00 and gave the stock an “outperform” rating in a research note on Friday, December 19th. Weiss Ratings restated a “buy (b)” rating on shares of HCA Healthcare in a report on Monday, December 29th. Wall Street Zen upgraded shares of HCA Healthcare from a “buy” rating to a “strong-buy” rating in a research note on Saturday, October 25th. The Goldman Sachs Group raised their price target on shares of HCA Healthcare from $470.00 to $520.00 and gave the company a “buy” rating in a report on Monday, October 27th. Finally, Stephens upped their price objective on shares of HCA Healthcare from $450.00 to $500.00 and gave the company an “overweight” rating in a research report on Monday, October 27th. Fifteen equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, HCA Healthcare has a consensus rating of “Moderate Buy” and a consensus target price of $487.00.

HCA Healthcare Company Profile

HCA Healthcare is a for‑profit operator of healthcare facilities headquartered in Nashville, Tennessee. Founded in 1968, the company owns and operates a network of hospitals and related healthcare facilities and has grown through organic expansion and acquisitions to become a large provider of inpatient and outpatient services.

The company’s core activities include the operation of acute care hospitals, freestanding surgical and emergency centers, and outpatient clinics. HCA’s services encompass inpatient care, surgical services, emergency medicine, diagnostic imaging and laboratory testing, and various outpatient and ambulatory care offerings.